Aldeyra Therapeutics (ALDX) News Today $5.84 -0.02 (-0.34%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.90 +0.07 (+1.11%) As of 08/29/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALDX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites ...August 28 at 8:52 PM | uk.finance.yahoo.comAldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal LymphomaAugust 28 at 7:01 AM | businesswire.comJonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9August 24, 2025 | finance.yahoo.comJonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9August 23, 2025 | insidermonkey.comAldeyra Therapeutics Gains FDA Fast Track for ADX-2191August 19, 2025 | msn.comAldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis PigmentosaAugust 19, 2025 | businesswire.comLeerink Partnrs Issues Positive Forecast for ALDX EarningsAugust 16, 2025 | marketbeat.comAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Insider Sells $113,675.95 in StockAugust 15, 2025 | marketbeat.comHC Wainwright Has Negative Outlook for ALDX Q3 EarningsAugust 15, 2025 | marketbeat.comAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Insider Stephen Machatha Sells 22,073 SharesAugust 14, 2025 | insidertrades.comWhat is HC Wainwright's Forecast for ALDX FY2029 Earnings?August 13, 2025 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above 50-Day Moving Average - Here's WhyAugust 13, 2025 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Issues Quarterly Earnings ResultsAugust 11, 2025 | marketbeat.comAldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 6, 2025 | businesswire.comAldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on ThursdayJuly 31, 2025 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Above 50 Day Moving Average - Should You Sell?July 26, 2025 | marketbeat.comAldeyra says FDA accepted resubmitted marketing application for lead drugJuly 17, 2025 | msn.comAldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseJuly 17, 2025 | businesswire.comAldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?July 15, 2025 | msn.comAldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Above 50-Day Moving Average - Should You Sell?July 8, 2025 | marketbeat.comAldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber DataJuly 2, 2025 | seekingalpha.comAldeyra stock jumps after FDA agreement on cancer drug trial designJune 26, 2025 | au.investing.comAldeyra Shares Climb on FDA Backing for PVRL Drug Trial DesignJune 26, 2025 | msn.comPFG Investments LLC Sells 295,997 Shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)June 26, 2025 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Upgraded to Hold at Wall Street ZenJune 21, 2025 | marketbeat.comAldeyra resubmits Reproxalap's marketing application to FDAJune 18, 2025 | msn.comAldeyra Therapeutics (NASDAQ:ALDX) Shares Pass Above Fifty Day Moving Average - What's Next?June 17, 2025 | marketbeat.com161,926 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Purchased by Millennium Management LLCJune 7, 2025 | marketbeat.comAldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | businesswire.comD. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)May 26, 2025 | marketbeat.comQ3 Earnings Forecast for ALDX Issued By Leerink PartnrsMay 24, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for ALDX EarningsMay 23, 2025 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Raised to "Sell" at StockNews.comMay 23, 2025 | marketbeat.comHC Wainwright Has Strong Estimate for ALDX FY2029 EarningsMay 22, 2025 | marketbeat.comAldeyra Therapeutics' (ALDX) "Buy" Rating Reiterated at HC WainwrightMay 21, 2025 | marketbeat.comAldeyra Therapeutics Inc.May 17, 2025 | barrons.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Purchased by Dimensional Fund Advisors LPMay 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDXMay 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXMay 12, 2025 | prnewswire.comALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)May 7, 2025 | globenewswire.comAldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens BermanMay 6, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXMay 6, 2025 | prnewswire.comInvesco Ltd. Cuts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)May 6, 2025 | marketbeat.comAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of ReproxalapMay 5, 2025 | finance.yahoo.comAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA ResubmissionMay 5, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXMay 5, 2025 | globenewswire.comShort Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Grows By 21.4%May 5, 2025 | marketbeat.comALDX SECURITIES ALERT: Lose Money on Aldeyra Therapeutics, Inc.? Contact BFA Law about Securities Investigation (NASDAQ:ALDX)May 5, 2025 | globenewswire.comALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations — Contact BFA LawMay 4, 2025 | morningstar.comM683 Capital Management LLC Purchases Shares of 290,000 Aldeyra Therapeutics, Inc (NASDAQ:ALDX)May 4, 2025 | marketbeat.com Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALDX Media Mentions By Week ALDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALDX News Sentiment▼0.631.05▲Average Medical News Sentiment ALDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALDX Articles This Week▼43▲ALDX Articles Average Week Get the Latest News and Ratings for ALDX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aldeyra Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies COGT News Today SPRY News Today PAHC News Today ABCL News Today EVO News Today TLRY News Today XERS News Today PGEN News Today ELVN News Today COLL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALDX) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.